UK Approves First Crispr Gene Edited Therapy For Sickle Cell Disease, Beta Thalassemia
Portfolio Pulse from Vandana Singh
The UK MHRA has granted conditional marketing authorization for Casgevy, a CRISPR/Cas9 gene-edited therapy for SCD and TDT, developed by Vertex Pharmaceuticals and CRISPR Therapeutics. The therapy has shown positive trial results and could replace bone marrow transplants, but it requires a complex administration process. VRTX shares closed at $349.34, and CRSP shares are up 4.93% in premarket trading.
November 16, 2023 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CRISPR Therapeutics' shares are up 4.93% in premarket trading following the UK approval of Casgevy, a gene therapy developed in partnership with Vertex Pharmaceuticals.
The news of Casgevy's approval is directly related to CRISPR Therapeutics and is expected to have a positive impact on the company's stock price in the short term, as evidenced by the premarket trading activity.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 80
POSITIVE IMPACT
Vertex Pharmaceuticals' gene therapy Casgevy received UK regulatory approval, indicating a significant milestone in the company's product pipeline.
The approval of Casgevy in the UK is a significant positive development for Vertex Pharmaceuticals, likely to boost investor confidence and potentially increase the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 80